A new drug has shown promise as a type 2 diabetes and weight loss treatment—potentially offering an new rival to drugs like Ozempic.

Ecnoglutide—a new once-weekly GLP-1 receptor agonist injection similar to both semaglutide (Ozempic) and dulaglutide (Trulicity)—appears to be effective for diabetes management.

In a Phase 3 randomized controlled trial, researchers at Fudan University and Hangzhou Sciwind Biosciences in China discovered that ecnoglutide it works as well as dulaglutide (a commonly prescribed once-a-week injection to manage diabetes) in lowering blood sugar levels.

Moreover, ecnoglutide may help patients lose more weight than dulaglutide, the researchers said.

In the U.S., more than 38 million Americans have diabetes (about 1 in 10), of which some 90–95 percent have type 2,

See Full Page